Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.
Also called NCT04433572
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 250 participants
- Sponsor
- Mercator MedSystems, Inc.
- Registry
-
NCT04433572
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT04433572. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-30 (actual); primary completion 2028-02-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
- Acronym
- TANGO-3
- Condition
- Peripheral Artery Disease
- Condition
- Critical Limb Ischemia
- Intervention (Drug)
- Temsirolimus
- Intervention (Drug)
- Saline placebo
- Lead sponsor
- Mercator MedSystems, Inc.
Record details
- Record id
cardio:ct-nct04433572- Content hash
67b9c50814b0374c41501f0b9b6f02015bd571c43cb597711b74f29e781ce272